We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Challenges of HexA delivery with AAV
- Solutions to challenges
- Basis for HexM engineering
- HexM requirements
- HexM structure
- HexM necessary mutations
- HexM modelling and interaction with GM2
- In vitro biochemical characterization of HexM
- HexM is twice as active as HexA
- Differential scanning fluorometry of HexM
- HexM activity in conditioned vs. control medium
- HEXA KO model accumulates GM2 in the CNS
- scAAV9 and 9.47 expression cassette design
- GM2 clearance by AAV9-Hex vectors: Trial 1
- Trial 1 results
- GM2 clearance by AAV9-Hex vectors: Trial 2
- Long-term GM2 clearance by scAAV9.47-HexM
- Sandhoff disease mouse model
- HexM delivery to Sandhoff disease mice
- GM2 storage and Hex activity
- Sandhoff disease mice survival curve
- Behavioral testing
- GM2 storage & Hex activity: end time point
- Vector distribution analysis
- Conclusions
Topics Covered
- Challenges of HexA delivery with AAV
- HexM modelling and interaction with GM2
- GM2 clearance by AAV9-Hex vectors
- HexM delivery to Sandhoff disease mice
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Mark, B. (2017, June 29). GM2 gangliosidosis future treatments 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved August 31, 2024, from https://doi.org/10.69645/KFGW1716.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Brian Mark has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
GM2 gangliosidosis future treatments 2
Published on June 29, 2017
19 min
A selection of talks on Neuroscience
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Brian Mark.
I'm an associate professor of microbiology at the University Manitoba.
This is the second half of a talk on the Future Treatments for GM2 Gangliosidosis.
0:13
For the remainder of my talk,
I'm now going to describe recent research that has exploited the features of
self-complementary adeno-associated virus 9 and its variant AAV
9.47 to correct both Sandhoff and Tay-Sachs disease in most models.
The following lists key challenges that one faces when
attempting to deliver HexA using self-complementary adeno-associated virus.
The heterodimeric nature of HexA makes
gene delivery challenging since the amount of DNA that is needed to
encode both the Alpha and Beta subunit of HexA
are about 1600 and 1700 base pairs respectively.
The two genes, together,
thus exceeds the packaging capacity of self-complementary adeno-associated virus.
Not to mention the additional DNA that is needed to
encode the promoter and enhancer elements that provide robust gene expression.
Packaging only a deficient subunit into
self-complementary adeno-associated virus would limit the level of
HexA to the endogenous partnering subunit which
would reduce the potential benefit of cross-correction.
Over expression of fully recombinant HexA would maximize secretion and
cross-correction thus both subunits should be packaged into the delivery virus.
Finally, co-administering two separate self-complementary adeno-associated viral vectors
and coding HexA and HexB would reduce
transduction efficiency since cells would need to be
transduced with both viruses in order to express fully recombinant HexA.
The solution to the limited size of the transgene that can be packaged into